ArticleGynecologic oncology reports2025

Early introduction of trastuzumab deruxtecan (T-DXd) in HER2 expressing rare gynecologic malignancies - How early is too early?

Jennifer McEachron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.